{"url":"https://lda.senate.gov/api/v1/filings/548845d0-bece-4e1a-9dc7-4c128e045d0e/","filing_uuid":"548845d0-bece-4e1a-9dc7-4c128e045d0e","filing_type":"Q2","filing_type_display":"2nd Quarter - Report","filing_year":2024,"filing_period":"second_quarter","filing_period_display":"2nd Quarter (Apr 1 - June 30)","filing_document_url":"https://lda.senate.gov/filings/public/filing/548845d0-bece-4e1a-9dc7-4c128e045d0e/print/","filing_document_content_type":"text/html","income":"30000.00","expenses":null,"expenses_method":null,"expenses_method_display":null,"posted_by_name":"Deborah Burrell","dt_posted":"2024-07-16T16:12:51-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"410 First Street, SE, Suite 300","registrant_address_2":null,"registrant_different_address":false,"registrant_city":"Washington","registrant_state":"DC","registrant_zip":"20003","registrant":{"id":401103483,"url":"https://lda.senate.gov/api/v1/registrants/401103483/","house_registrant_id":null,"name":"BURRELL INTERNATIONAL GROUP LLC","description":"Government Affairs Firm","address_1":"410 First Street, SE, Suite 200","address_2":null,"address_3":null,"address_4":null,"city":"Washington","state":"DC","state_display":"District of Columbia","zip":"20003","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"MARK W. WARD","contact_telephone":"+1 888-658-8484","dt_updated":"2026-01-28T12:42:37.742222-05:00"},"client":{"id":54067,"url":"https://lda.senate.gov/api/v1/clients/54067/","client_id":54067,"name":"SHIONOGI INC.","general_description":"Pharmaceutical Company","client_government_entity":null,"client_self_select":false,"state":"NJ","state_display":"New Jersey","country":"US","country_display":"United States of America","ppb_state":"NJ","ppb_state_display":"New Jersey","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2022-12-15"},"lobbying_activities":[{"general_issue_code":"PHA","general_issue_code_display":"Pharmacy","description":"FY25 Appropriations and policy for the Strategic National Stockpile, BARDA, and Industrial Base Management Supply Chain, Pandemic and All Hazards Preparedness Act (PAHPA), PASTEUR Act and MCM Development funding.","foreign_entity_issues":"Shionogi, Inc. is a domestic, US corporation which is 100% owned by a foreign parent. Lobbying efforts may benefit the foreign parent tangentially.","lobbyists":[{"lobbyist":{"id":139243,"prefix":null,"prefix_display":null,"first_name":"KRISTIN","nickname":null,"middle_name":null,"last_name":"STEVENS","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":61445,"prefix":null,"prefix_display":null,"first_name":"DEBORAH","nickname":null,"middle_name":"LYNN","last_name":"BURRELL","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]}